Publications by authors named "S Hildemann"
Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is expected throughout the development and delivery of medicine, healthcare, and information, and potential sources of evidence are legion.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated the safety of a reformulated levothyroxine sodium in France, prompted by a request for stricter potency specifications, after an increase in reported adverse events despite previous bioequivalence and purity assurance.
- - Data from safety reports were collected for both old and new formulations, showing a stark increase in total reports for the new formulation, but with most adverse events being non-serious and rates generally comparable between the two formulations.
- - The analysis concluded that the new formulation has a safety profile similar to the old one, indicating that the overall benefits of the new treatment still outweigh the risks associated with its use.
Hypertension is currently one of the greatest global health care challenges. Although many effective drugs are available, combinations of 2 or more medications are often required to meet clinical targets. Combination therapy has several advantages over monotherapy: lower doses of each drug can be used to achieve therapeutic goals; lower doses may lead to fewer adverse events, facilitating patient adherence; and using multiple drugs with different modes of action may be more effective in treating multifactorial diseases, including hypertension.
View Article and Find Full Text PDFAims: Disease management programs (DMP) for diabetes mellitus (DM) or coronary heart disease (CHD) address the treatment of lipid disorders. The current registry aimed to compare drug utilization, lipid lowering effects and further outcomes of outpatients at high cardiovascular risk in DMP for DM or CHD compared to patients in routine care (no-DMP).
Methods: This was a prospective non-interventional registry with a 1 year follow-up which enrolled consecutive patients with known DM and/or any vascular disease on simvastatin 40 mg monotherapy, to document lipid target achievement in clinical practice in Germany according to existing guidelines.